Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Definitions

• the gonadotropin-releasing hormone also referred to as luteinizing hormone-releasing hormone (LHRH)
• LHRH luteinizing hormone-releasing hormone
• the hormone is released from the hypothalamus and acts on the pituitary gland to stimulate the biosynthesis and secretion of luteinizing hormone (LH) and follicle- stimulating hormone (FSH).
• LH released from the pituitary gland is primarily responsible for the regulation of gonadal steroid production in both sexes, whereas FSH regulates spermatogenesis in males and follicular development in females.
• GnRH agonists and antagonists have proven effective in the treatment of certain conditions which require inhibition of LH FSH release.
• GnRH-based therapies have proven effective in the treatment of endometriosis, uterine fibroids, polycystic ovarian disease, precocious puberty and several gonadal steroid-dependent neoplasia, most notably cancers of the prostate, breast and ovary.
• GnRH agonists and antagonists have also been utilized in various assisted fertilization techniques and have been investigated as a potential contraceptive in both men and women.
• the compounds of the invention may also be used in combination with bisphosphonates (bisphosphonic acids) and other agents, such as growth hormone secretagogues, for the treatment and the prevention of disturbances of calcium, phosphate and bone metabolism, in particular, for the prevention of bone loss during therapy with the GnRH antagonist, and in combination with estrogens, progesterones, antiestrogens, antiprogestins and/or androgens for the prevention or treatment of bone
• a compound of the present invention may be co-administered with a 5a-reductase 2 inhibitor, such as finasteride or epristeride; a 5a-reductase 1 inhibitor such as 4,7b-dimethyl-4-aza-5a- cholestan-3-one, 3-oxo-4-aza-4,7b-dimethyl-16b-(4-chlorophenoxy)-5a- androstane, and 3-oxo-4-aza-4,7b-dimethyl-16b-(phenoxy)-5a-androstane as disclosed in WO 93/23420 and WO 95/11254; dual inhibitors of 5a- reductase 1 and 5a-reductase 2 such as 3-oxo-4-aza-17b-(2,5- trifluoromethylphenyl-carbamoyl)-5a-androstane as disclosed in WO 95/07927; antiandrogens such as flutamide, casodex and c
• a compound of the present invention may be used in combination with growth hormone, growth hormone releasing hormone or growth hormone secretagogues, to delay puberty in growth hormone deficient children, which will allow them to continue to gain height before fusion of the epiphyses and cessation of growth at puberty.
• a compound of the present invention may be used in combination or co-administered with a compound having luteinizing hormone releasing activity such as a peptide or natural hormone or analog thereof.
• a compound having luteinizing hormone releasing activity such as a peptide or natural hormone or analog thereof.
• peptide compounds include leuprorelin, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterlin and recirelin.
• a compound of the present invention may be used as described in U.S. Patent No.
• 5,824,286 which discloses the administration of peptide GnRH antagonists such as Antide and azaline B to premenopausal women to enhance the readability of mammographic film relative to a mammogram effected in the absence of the administration.
• GnRH antagonists are GnRH-like decapeptides which are generally administered intravenously or subcutaneously presumably because of negligible oral activity. These have amino acid substitutions usually at positions one, two, three, six and ten.
• Non-peptide GnRH antagonists offer the possible advantage of oral adminstration.
• Non-peptide GnRH antagonists have been described in European Application 0 219 292 and in De, B. et al., J. Med. Chem., 32, 2036-2038 (1989), in WO 95/28405, WO 95/29900 and EP 0679642 all to Takeda Chemical Industries, Ltd.
• Substituted indoles known in the art include those described in the following patents and patent applications.
• US Patent No. 5,030,640 discloses alpha-heterocyclic ethanol aminoalkyl indoles which are potent ⁇ -agonists.
• US Patent No. 4,544,663 discloses indolamine derivatives which are allegedly useful as male anti-fertility agents.
• WO 90/05721 discloses alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents.
• French patent 2,181,559 discloses indole derivatives with sedative, neuroleptic, analgesic, hypotensive, antiserotonin and adrenolytic activity.
• Belgian patent 879381 discloses 3-aminoalkyl-lH-indole-5-thioamide and carboxamide derivatives as cardiovascular agents used to treat hypertension, Raynaud's disease and migraine.
• U.S. Patent Nos. 5,756,507, 5,780,437 and 5,849,764 also disclose substituted arylindoles as non-peptide antagonists of GnRH.
• the present invention relates to compounds which are non-peptide antagonists of GnRH which can be used to treat a variety of sex-hormone related conditions in men and women, to methods for their preparation, and to methods and pharmaceutical compositions containing said compounds for use in mammals.
• the compounds of the present invention are useful to treat a variety of sex-hormone related conditions in both men and women. These conditions include endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid- dependent neoplasias such as cancers of the prostate, breast and ovary, gonadotrophe pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome and benign prostatic hypertophy.
• the compounds of the invention are also useful as an adjunct to treatment of growth hormone deficiency and short stature, and for the treatment of systemic lupus erythematosis.
• the compounds of the invention may be useful in in vitro fertilization and as contraceptives.
• the compounds may also be useful in combination with androgens, estrogens, progesterones, antiestrogens and antiprogestogens for the treatment of endometriosis, fibroids and in contraception. They may also be useful in combination with testosterone or other androgens or antiprogestogens in men as a contraceptive.
• the compounds may also be used in combination with an angiotensin-converting enzyme inhibitor such as Enalapril or Captopril, an angiotensin II-receptor antagonist such as Losartan or a renin inhibitor for the treatment of uterine fibroids.
• an angiotensin-converting enzyme inhibitor such as Enalapril or Captopril
• an angiotensin II-receptor antagonist such as Losartan or a renin inhibitor
• the compounds of the invention may also be used in combination with bisphosphonates (bisphosphonic acids) and other agents, for the treatment and the prevention of disturbances of calcium, phosphate and bone metabolism, in particular, for the prevention of bone loss during therapy with the GnRH antagonist, and in combination with estrogens, progesterones and/or androgens for the prevention or treatment of bone loss or hypogonadal symptoms such as hot flashes during therapy with the GnRH antagonist.
• a compound of the present invention may be co-administered with a 5a-reductase 2 inhibitor, such as fmasteride or epristeride; a 5a-reductase 1 inhibitor such as 4,7b-dimethyl-4-aza-5a- cholestan-3-one, 3-oxo-4-aza-4,7b-dimethyl-16b-(4-chlorophenoxy)-5a- androstane, and 3-oxo-4-aza-4,7b-dimethyl-16b-(phenoxy)-5a-androstane as disclosed in WO 93/23420 and WO 95/11254; dual inhibitors of 5a- reductase 1 and 5a-reductase 2 such as 3-oxo-4-aza-17b-(2,5- trifluoromethylphenyl-carbamoyl)-5a-androstane as disclosed in WO 95/07927; antiandrogens such as flutamide, casodex and c
• a compound of the present invention may be used in combination with growth hormone, growth hormone releasing hormone or growth hormone secretagogues, to delay puberty in growth
• a compound of the present invention may be used in combination or co-administered with a compound having luteinizing hormone releasing activity such as a peptide or natural hormone or analog thereof.
• a compound having luteinizing hormone releasing activity such as a peptide or natural hormone or analog thereof.
• peptide compounds include leuprorelin, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterlin and recirelin.
• a compound of the present invention may be used as described in U.S. Patent No. 5,824,286 which discloses the administration of peptide GnRH antagonists such as Antide and azaline B to premenopausal women to enhance the readability of mammographic film relative to a mammogram effected in the absence of the administration.
• peptide GnRH antagonists such as Antide and azaline B
• the present invention relates to compounds of the general formula
• A is Cl-C ⁇ alkyl, substituted Ci-C ⁇ alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C6 alkenyl, substituted C3-C6 alkenyl, C3-C6 alkynyl, substituted C3-C6 alkynyl, C1-C6 alkoxy, or C0-C5 alkyl-S(O) n -Co-C5 alkyl, C0-C5 alkyl- O-C0-C5 alkyl, C0-C5 alkyl-NRi8-Co-C5 alkyl where Ri8 and
• the C0-C5 alkyl can be joined to form a ring
• R ⁇ is hydrogen, Cl-C ⁇ alkyl, substituted C1-C6 alkyl, wherein the substituents are as defined below; aryl, substituted aryl, aralkyl or substituted aralkyl, wherein the substituents are as defined for R3, R4 and R5;
• Y is B, C or a bond
• B is O, S(O) n , C(O), NR18 or C(RnRi2)p
• C is B(CH 2 )p-;
• R2 is hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl, aralkyl, substituted aralkyl, aryl, substituted aryl, alkyl -ORn,
• R3, R4 and R5 are independently hydrogen, Cl-C ⁇ alkyl, substituted
• R3 and R4 taken together form a carbocyclic ring of 3-7 carbon atoms or a heterocyclic ring containing 1-3 heteroatoms selected from N, O and S;
• R ⁇ is hydrogen, Cl-C ⁇ alkyl, substituted Cl-C ⁇ alkyl, aryl, substituted aryl, C1-C3 perfluoroalkyl, CN, NO2, halogen, RllO(CH2)p-, NR ⁇ 2 C(O)Rn, NR ⁇ 2 C(O)NRnRi2 or SO n Rli;
• R7 is hydrogen, Cl-C ⁇ alkyl, or substituted Cl-C ⁇ alkyl, unless X is hydrogen or halogen, then R7 is absent;
• R8 is hydrogen, C(O)OR9, C(O)NRnRi2, NR11R12, C(O)Rn,
• NRi2C(O)Rn NRi2C(O)NR ⁇ iRi2, NRi2S(0)2Rll, NRi 2 S(O) 2 NRiiRi2, OC(0)Rn, OC(O)NRnR ⁇ 2 , ORn, SO n Rn, S(O) n NRnRi2, Cl-C ⁇ alkyl or substituted Cl-C ⁇ alkyl, unless X is hydrogen or halogen, then Rs is absent; or
• R9 and Rg a are independently hydrogen, Cl-C ⁇ alkyl, substituted Cl-C ⁇ alkyl; aryl or substituted aryl, aralkyl or substituted aralkyl when m ⁇ O; or
• R9 and Rg a taken together form a carbocyclic ring of 3-7 atoms or when m ⁇ O;
• RlO and RlOa are independently hydrogen, Cl-C ⁇ alkyl, substituted Cl-C ⁇ alkyl, aryl, substituted aryl, aralkyl or substituted aralkyl; or
• RlO and RlOa taken together form a carbocyclic ring of 3-7 atoms or ;
• R9 and R2 taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms when m ⁇ O; or RlO and R2 taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms; Rio and A taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms; or Rll and R12 are independently hydrogen , Cl-C ⁇ alkyl, substituted Cl-C ⁇ alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, a carbocyclic ring of 3-7 atoms or a substituted carbocyclic ring containing 3-7 atoms; Rll and Ri2 taken together can form an optionally substituted ring of 3-7 atoms;
• Rl3 is hydrogen, OH, NR7R8, NRnS ⁇ 2(Ci-C ⁇ alkyl),
• Rl4 and R15 are independently hydrogen, Cl-C ⁇ alkyl, substituted Cl-C ⁇ alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, CN, nitro, C1-C3 perfluoroalkyl, C1-C3 perfluoroalkoxy, aryl, substituted aryl, aralkyl, substituted aralkyl, RnO(CH2)p-, RllC(0)0(CH2)p-, RnOC(0)(CH2)p-, -(CH 2 ) p S(O) n Rl7, -(CH2)pC(O)NRnRi2 or halogen; wherein R17 is hydrogen, Cl-C ⁇ alkyl, C1-C3 perfluoroalkyl, aryl or substituted aryl; Ri ⁇ is hydrogen, Cl-C ⁇ alkyl, substituted Cl-C ⁇ alkyl, or
• Rl8 is hydrogen, Cl-C ⁇ alkyl, substituted Cl-C ⁇ alkyl, C(O)OR9,
• X is hydrogen, halogen, N, O, S(O) n , C(O), (CRnRi2) p ; C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, or substituted C2-C6 alkynyl; when X is hydrogen or halogen, R7 and Rs are absent; when X is O, S(O)n, C(O), or CR11R12 only R7 or Rs is possible; m is 0-3; n is 0-2; p is 0-4; and the alkyl, cycloalkyl, alkenyl and alkynyl substituents are selected from Cl-C ⁇ alkyl, C3-C7 cycloalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, hydroxy, oxo, cyano, Cl-C ⁇ alkoxy, fluoro, C(O)ORii ⁇ ary
• any variable e.g., aryl, heterocycle, Ri, etc.
• its definition on each occurrence is independent of its definition at every other occurrence.
• combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
• alkyl is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, e.g., methyl (Me), ethyl (Et), propyl, butyl, pentyl, hexyl, heptyl, octyl, nonanyl, decyl, undecyl, dodecyl, and the isomers thereof such as isopropyl (i-Pr), isobutyl (i-Bu), sec-butyl
• aryl includes phenyl and naphthyl. In a preferred embodiment, aryl is phenyl.
• halogen or halo is intended to include fluorine, chlorine, bromine and iodine.
• heterocycle or “heterocyclic ring” is defined by all non-aromatic, heterocyclic rings of 3-7 atoms containing 1-3 heteroatoms selected from N, O, and S, such as oxirane, oxetane, tetrahydrofuran, tetrahydropyran, pyrrolidine, piperidine, tetrahydropyridine, tetrahydropyrimidine, tetrahydrothiophene, tetrahydrothiopyran, morpholine, hydantoin, valerolactam, pyrrolidinone, and the like.
• composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts
• the individual optical isomers may be prepared using conventional resolution procedures, e.g., treatment with an appropriate optically active acid, separating the diastereomers and then recovering the desired isomer.
• the individual optical isomers may be prepared by asymmetric synthesis.
• a given chemical formula or name shall encompass pharmaceutically acceptable addition salts thereof and solvates thereof, such as hydrates.
• the compounds of the present invention while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable addition salts for purposes of stability, convenience of crystallization, increased solubility and other desirable properties.
• the compounds of the present invention may be administered in the form of pharmaceutically acceptable salts.
• pharmaceutically acceptable salt is intended to include all acceptable salts. Examples of acid salts are hydrochloric, nitric,
• salts of the compounds of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide.
• bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethan
• esters can be employed, e.g. methyl, ethyl, butyl, acetate, maleate, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.
• the compounds of the present invention may have chiral centers other than those centers whose stereochemistry is depicted in formula I, and therefore may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers, with all such isomeric forms being included in the present invention as well as mixtures thereof.
• crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention.
• some of the compounds of the instant invention may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of this invention.
• a preferred method for the synthesis of the substituted tryptamines described in this invention utilizes a palladium-catalyzed cross coupling reaction as a key step as shown in Scheme A.
• This 7- azaindole synthesis involves the reaction of a suitably functionalized 3- iodo-2-aminopyridine (1) with substituted acetylenes such as 2 in the presence of a base like sodium carbonate, lithium chloride, and a palladium catalyst such as (dppf)PdCl 2 *CH 2 Cl 2 .
• the reaction is conducted in an inert organic solvent such as dimethylformamide at elevated temperatures, for instance at 100°C, and the reaction is conducted for a period of about 30 minutes to about 24 hours.
• a standard workup and isolation affords the substituted isomeric indole derivatives 3 and 4, and the isomer of general formula 3 is the preferred isomer.
• the acetylene utilized in this reaction may be a terminal acetylene (2a) or be optionally substituted on the terminal carbon atom with a substituent Z (2b, 2c).
• the substituent abbreviated PG X indicates an alcohol protecting group such as a benzyl ether, tert-butyl ether or the like.
• the nature of the Z substituent determines the distribution of the 7- azaindole isomers (3 and 4) produced in the reaction. For example, if the substituent Z on the acetylene is a hydrogen atom then the isomer 4a is the major product of the reaction.
• Scheme B illustrates the preparation of substituted 3- iodo-2-aminopyridines (1) which are utilized in the Larock 7-azaindole synthesis described in Scheme A.
• the 3-iodo-2-aminopyridines (1) may be prepared in several ways described in the literature of organic synthesis.
• a preferred method involves the or ⁇ o-iodination of substituted 2-aminopyridine derivatives of general formula 9 with an electrophilic iodination reagent such as iodine, iodine monochloride, iV-iodosuccinimide or the like.
• 2-aminopyridine derivatives such as 9 may be commercially available or alternatively they may be prepared using methodologies known in organic chemistry. For instance, application of methodology reported by Wachi and Terada (Wachi, K.; Terada, A. Chem. Pharm. Bull. 1980, 28, 465) allows the conversion of pyridines of general formula 5 to 2-aminopyridines of general formula 9 as shown at
• Acetylenic compounds of general structure 2 are prepared using one of several methods depending upon the choice of the desired
• reaction of 10 with 0-benzyl-2,2,2-trichloro- acetimidate in the presence of a catalytic amount of a strong acid such as trifluoromethanesulfonic acid and in a suitable inert organic solvent like carbon tetrachloride at room temperature affords after 2 to 24 hours the protected acetylenic alcohol 2a.
• Compounds of formula 2a may in turn be converted to acetylenes (2b) of general formula 2 wherein Z is a trialkylsilyl group by deprotonation of the acetylene with a base such as ⁇ .-butyllithium in an inert organic solvent like tetrahydrofuran followed by reaction with a trialkylsilyl chloride such as triethylchlorosilane.
• the deprotonation and silylation reactions are generally conducted at low temperatures, for instance between about -78°C and room temperature, and after standard workup and purification a silylacetylene of formula 2b is obtained.
• acetylenes of general formula 2c wherein Z is an aryl or substituted aryl group are also useful in the 7- azaindole synthesis illustrated in Scheme A.
• Arylacetylenes 2c may be prepared using a coupling reaction of cuprous acetylides derived from acetylenic alcohols of formula 2a with various aryl halides or aryl triflates (11). Such coupling reactions produce aryl acetylenes of general formula 12 as shown at the bottom of Scheme C.
• arylacetylene (2c) of general formula 2 wherein Z is an aryl or substituted aryl group. It is also recognized that in some cases it may be preferable to reverse the order of the steps illustrated in Scheme C. For instance, acetylenic alcohols (7) may be subjected to silylation or arylation prior to the hydroxyl group protection step.
• acetylenic compounds of general formula 2a employs an ethynylation reaction sequence of aldehydes of general formula 16 as shown in Scheme D.
• the aldehydes (16) used in the ethynylation sequence may be prepared using various methods known in organic synthesis starting with hydroxy- esters of general formula 13, from protected hydroxyesters of formula 14, or from alcohols related to the mono-hydroxyl protected diols of formula 15. The choice of preferred starting material depends upon the nature of the substituents R 9 , R 9a , R 10 , and R 10a selected.
• Scheme D illustrates this strategy begining with the generalized hydroxy ester 13. Protection of the hydroxyl group of 13, for instance as the O-benzylether shown,
• ester group of compounds of formula 14 can then be converted to an aldehyde of formula 16 either directly using a reagent like diisobutylaluminum hydride in a solvent like toluene, or through a two step process.
• a reagent like diisobutylaluminum hydride in a solvent like toluene
• reduction of the ester group with a reagent such as lithium aluminum hydride in tetrahydrofuran affords alcohols of formula 15 which are then subjected to reoxidation, for instance using a Swern-Moffatt oxidation, to afford the desired aldehydes of formula 16.
• aldehydes of formula 16 The ethynylation of aldehydes of formula 16 is accomplished in two steps. First, aldehydes (16) are reacted with carbon tetrabromide and triphenylphosphine in an inert organic solvent like dichloro- methane to produce the dibromo olefins of formula 17. Next, the dibromo olefins (17) are treated with two equivalents of a strong base such as ft-butyllithium in tetrahydrofuran at low temperature, for instance at about -78°C.
• a strong base such as ft-butyllithium in tetrahydrofuran
• the strong base induces dehydrohalogenation and metal- halogen exchange to afford lithium acetylides which upon quenching and workup afford acetylenes of general formula 2a.
• the intermediate lithium acetylides formed in the reaction may be treated with a trialkylsilyl chloride, such as triethylchlorosilane, to afford silylacetylenes of general formula 2b.
• the conversion of 2-silyl-substituted 7-azaindoles of general formula 3b to 2-aryl-substituted 7-azaindoles of general formula 3c may be accomplished in two steps as shown in Scheme E.
• the first step is a halodesilylation reaction which converts silyl-substituted 7-azaindoles of formula 3b into 2-halo-7-azaindoles of general formula 18.
• Scheme E illustrates this process using iodine monochloride so that the product obtained is a 2-iodoindole of general formula 18.
• Silver tetrafluoro- borate is also employed in this example to increase the reactivity of the halogenating reagent.
• the second step is a palladium-catalyzed cross coupling reaction of the 2-halo-7-azaindole 18 with a suitable aryl or substituted aryl organometallic reagent 19.
• Scheme E illustrates this process with an aryl or substituted arylboronic acid as the organometallic reagent, however, other organometallic reagents known to participate in palladium-catalyzed cross-coupling reactions such as arylboronic esters or arylstannanes may also be employed.
• a 2-iodo-7- azaindole of general formula 18 is coupled with a generalized boronic acid (19) using a catalyst such as [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) complex with dichloromethane (shown), tetrakis(triphenylphosphine)-palladium(0) or the like.
• a catalyst such as [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) complex with dichloromethane (shown), tetrakis(triphenylphosphine)-palladium(0) or the like.
• the reaction is usually conducted at temperatures between room temperature and about 100°C, for instance at about 80°C.
• This palladium catalyzed cross- coupling reaction may be effected using various combinations of palladium catalysts and solvent compositions known in organic chemistry, and the selection of the conditions is made depending upon the type of organometallic reagent (19) used and the identity of the substituent groups in the two starting materials.
• organometallic reagent is a boronic acid or boronate ester
• a preferred solvent mixture consists of toluene, ethanol and an aqueous solution of
• organometallic reagent 19 a base like cesium or sodium carbonate. If instead the organometallic reagent 19 is an arylstannane, then no additional base is required, and a polar aprotic solvent such as tetrahydrofuran or dimethylformamide is employed.
• R 10 R 10 a imidazole, CH 2 C1 2 it, 1-24 h
• the hydroxyl group of 21 is converted to a primary amine of general formula 23 which is then further functionalized as shown below in the following schemes.
• the choice of an appropriate amine protecting group (PG 2 ) for the 7-azaindole is determined primarily by which protecting group (PG ⁇ ) is present on the hydroxyl group in the C-3 sidechain, and by consideration of the chemical stability of the amine protecting group (PG X ) required in the remaining steps of the synthesis.
• the hydroxyl protecting group (PG ⁇ ) is anO -benzyl ether as illustrated previously in Schemes C and D
• the 7-azaindole may be protected as a carbamate derivative such as a ter£-butylcarbamate (BOC).
• the BOC-protected 7-azaindole is stable under the hydrogenolysis conditions which are used to remove the O-benzyl ether and it may be conveniently removed at the end of the synthesis using acidic conditions. If it is desired to synthesize compounds of formula (I) wherein R 0 is alkyl, substituted alkyl or the like, then it is possible to introduce that substituent at this point and the use of a protecting group and its subsequent removal is not required.
• An alcohol of general formula 21 may be converted to a primary amine of general formula 23 using a variety of methods known in the literature of organic chemistry.
• the bottom of Scheme F illustrates a process where the alcohol 21 is first converted to an azide of general formula 22, followed by reduction to afford the amine derivative 23.
• the synthesis of an azide of general formula 22 from alcohols like 21 is best accomplished by performing a Mitsunobu reaction in the presence of an appropriate azide source such as diphenylphosphoryl azide or zinc azide pyridine complex.
• Scheme F illustrates the reaction of alcohol 21 with triphenylphosphine, diethylazodicarboxylate, zinc azide pyridine complex and a proton source such as imidazole in an inert solvent like methylene chloride or tetrahydrofuran.
• the reaction is usually conducted at room temperature for periods between 1-24 hours, typically overnight or about 15 hours, and affords the azide of general formula 22 in good yield.
• an azide of formula 22 may then be reduced to an amine of formula 23 using one of several methods common in organic synthesis.
• One preferred method is catalytic
• the final stage of the synthesis of the novel 7-azaindole derivatives (I) involves elaboration of the sidechain at the C-3 position of the 7-azaindole core.
• One method for the completion of the synthesis is illustrated in Scheme G.
• the 2-aryltryptamine (23) may be condensed with a carboxylic acid of type 24 using the coupling reagent l-(3-dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride (EDC), 1,3-dicyclohexyl-carbodiimide (DCC) or the like with or without 1- hydroxybenzotriazole (HOBt) and a tertiary amine base such as iV-methylmorpholine (NMM), triethylamine or the like in an inert organic solvent such as methylene chloride, chloroform, dimethylformamide, or mixtures thereof at or near room temperature for a period of 3-24 hours to provide the corresponding
• 2-aryltryptamine 23 can be treated with an active ester or acid chloride of formula 26 in an inert organic solvent such as methylene chloride, chloroform, tetrahydrofuran, diethyl ether, or the like and a tertiary amine base such as triethylamine,
• the amide carbonyl of 25 can be reduced by treatment with borane, lithium aluminum hydride, or equivalent hydride sources in an inert organic solvent such as tetrahydrofuran, diethyl ether, 1,4-dioxane or the like at about 25° to about 100°C, preferably about 65°C, for a period of 1-8 hours to give the corresponding amine 27.
• borane, lithium aluminum hydride, or equivalent hydride sources in an inert organic solvent such as tetrahydrofuran, diethyl ether, 1,4-dioxane or the like at about 25° to about 100°C, preferably about 65°C, for a period of 1-8 hours to give the corresponding amine 27.
• the 2-aryltryptamine 23 can be modified by treatment with an aldehyde or ketone of type 28 in the presence of a weak acid such as trifluoroacetic acid (TFA), acetic acid or the like, with or without a dessicant such as 3A molecular sieves or
• the tryptamine 23 can be modified using the Fukuyama modification of the Mitsunobu reaction (Fukuyama, T.; Jow, C.-K; Cheung, M. Tetrahedron Lett. 1995, 36, 6373- 74).
• the tryptamine 23 may be reacted with an arylsufonyl chloride such as 2-nitrobenzene-sulfonyl chloride, 4-nitrobenzenesulfonyl chloride or 2,4-dinitrobenzene-sulfonyl chloride and a hindered amine base such as 2,4,6-collidine, 2,6-lutidine or the like in an inert organic solvent such as methylene chloride to provide the corresponding sulfonamide 30.
• the sulfonamides can be further modified by reaction with an alcohol of type 31 in the presence of triphenylphosphine and an activating agent such
• DEAD diethylazodicarboxylate
• diisoprop lazodicaboxylate or the like inert organic solvent such as benzene, toluene, tetrahydrofuran or mixtures thereof to give the dialkylsulfonamide adduct.
• DEAD diethylazodicarboxylate
• benzene, toluene, tetrahydrofuran or mixtures thereof to give the dialkylsulfonamide adduct.
• Removal of a dinitrobenzenesulfonyl group is accomplished by treatment with a nucleophilic amine such as rc-prop lamine or the like in an inert organic solvent such as methylene chloride to give secondary amines of type 32.
• a mono-nitrobenzenesulfonyl derivative When a mono-nitrobenzenesulfonyl derivative is employed, the removal of the sulfonamide is accomplished with a more nucleophilic reagent such as thiophenol or mercaptoacetic acid in combination with lithium hydroxide in DMF.
• a more nucleophilic reagent such as thiophenol or mercaptoacetic acid in combination with lithium hydroxide in DMF.
• Reaction Scheme K illustrates a method that is complimentary to reaction Scheme J for completing the synthesis of the novel compounds of formula (I).
• Scheme K also employs the Fukuyama modification of the Mitsunobu reaction similar to that illustrated in reaction Scheme J.
• the alcohol partner employed is a 2-aryltryptophol of general formula 21 which has been decribed previously in reaction Scheme F.
• the 2-aryltryptophol (21) is reacted with a substituted sulfonamide of general formula 33,
• triphenylphosphine and diethylazodicarboxylate in a suitable inert organic solvent such as benzene, tetrahydrofuran, 1,4-dioxane or the like.
• a suitable inert organic solvent such as benzene, tetrahydrofuran, 1,4-dioxane or the like.
• the reaction is generally conducted at room temperature for a period of 2 to 24 hours, typically overnight or for about 12-16 hours.
• the product is an iST ⁇ N-disubstituted sulfonamide which is then separately subjected to reaction with a base such as / ⁇ -propylamine which removes the sulfonamide substituent and furnishes a secondary amine related to formula 32.
• the sulfonamides of formula 33 employed are readily obtained from a primary amine and either 2-nitrobenzenesulfonyl chloride, 4-nitrobenzenesulfonyl chloride or 2,4-dinitrobenzenesulfonyl chloride (as shown) in the presence of a hindered amine base such as 2,4,6-collidine, 2,6-lutidine or the like in an inert organic solvent such as methylene chloride.
• PG 2 7-azaindole nitrogen atom
• the ligand binding assay is conducted with the human GnRH receptor (hGnRHR) obtained from CHO-K1 cells stably expressing the cloned receptor. Crude membrane suspensions are prepared from large batches of hGnRHR-CHO-Kl cells and stored as aliquots at -80°C .
• the radioactive peptide ligand [5-( 125 Iodo-Tyr)-Buserelin] is obtained from Woods Assays (Portland, Oregon) and has a radioactive specific activity of 1000 Ci mmol.
• the membranes and the radioligand are diluted in assay buffer which consists of 50 mM Tris-HCl (pH 7.5), 2 M
• the ligand binding assay is performed at 22°C for 1 hour in 96-well polypropylene plates in a final volume of 200 ul. Each well in the assay plate contains 0.1 nlvl 125 I- buserelin, 10-15 ug of hGnRH receptor-membrane protein and the test compound. Test compounds are examined over a range of concentrations from 0.01 to 10,000 nM. The incubation is terminated by vacuum filtration onto 96-well Packard GF/C Unifilter plates (pretreated with 0.1% polyethyleneimine) and then washed with 2 mL of cold phosphate buffered saline (pH 7.5). The Unifilter plates are dried prior to addition of scintillation fluid and counting in a Packard TopCount detector
• Chinese hamster ovary cell lines expressing the human GnRH receptor functionally coupled to phospholipase C were established and seeded at a concentration of 60,000 cells/mL/well in inositol-free F12 medium containing 10% dialyzed fetal bovine serum, 1% Pen/Strep, 2 mM glutamine, 500 ⁇ g/mL G418 and 1 ⁇ Ci ( 3 H)inositol in 24-well tray. Forty-eight hours after seeding, cells were washed with 3 x 1 mL of PBS containing 10 mM LiCl and treated with various concentrations of
• GnRH antagonist for 2 hrs at 37°C before the addition of 0.5 nM GnRH. After incubation at 37°C for an additional 60 min, the medium was removed and the cells were lysed with 1 mL of 0.1 M formic acid. The trays were freeze-thawed once and the cell extract was applied onto a Dowex AG1-X8 column. The column was washed with 2 x 1 mL H 2 O to remove free ( 3 H)inositol and ( 3 H)inositol phosphates were eluted with 3 x 1 mL 2 M ammonium formate in IM formic acid. The eluate was then counted in a scintillation counter.
• the compounds of formula I are useful in a number of areas affected by GnRH. They may be useful in sex-hormone related conditions, sex-hormone dependent cancers, benign prostatic hypertrophy or myoma of the uterus. Sex-hormone dependent cancers which may benefit from the administration of the compounds of this invention include prostatic cancer, uterine cancer, breast cancer and
• 27 pituitary gonadotrophe adenomas.
• Other sex-hormone dependent conditions which may benefit from the administration of the compounds of this invention include endometriosis, polycystic ovarian disease, uterine fibroids and precocious puberty.
• the compounds may also be used in combination with an angiotensin-converting enzyme inhibitor such as Enalapril or Captopril, an angiotensin II-receptor antagonist such as Losartan or a renin inhibitor for the treatment of uterine fibroids.
• the compounds of the invention may also be useful for controlling pregnancy, as a contraceptive in both men and women, for in vitro fertilization, in the treatment of premenstrual syndrome, in the treatment of lupus erythematosis, in the treatment of hirsutism, in the treatment of irritable bowel syndrome and for the treatment of sleep disorders such as sleep apnea.
• a further use of the compounds of this invention is as an adjunct to growth hormone therapy in growth hormone deficient children.
• the compounds may be administered with growth hormone or a compound which increases the endogenous production or release of growth hormone. Certain compounds have been developed which stimulate the release of endogenous growth hormone.
• Peptides which are known to stimulate the release of endogenous growth hormone include growth hormone releasing hormone, the growth hormone releasing peptides GHRP-6 and GHRP-1 (described in U.S. Patent No. 4,411,890, PCT Patent Pub. No. WO 89/07110, and PCT Patent Pub. No. WO 89/07111) and GHRP-2 (described in PCT Patent Pub. No.
• Representative preferred growth hormone secretagoues employed in the present combination include the following:
• the compounds of the invention may also be used in combination with bisphosphonates (bisphosphonic acids) and other agents, such as growth hormone secretagogues, for the treatment and the prevention of disturbances of calcium, phosphate and bone metabolism, in particular, for the prevention of bone loss during therapy with the GnRH antagonist, and in combination with estrogens, progesterones and or androgens for the prevention or treatment of bone loss or hypogonadal symptoms such as hot flashes during therapy with the GnRH antagonist.
• bisphosphonates bisphosphonic acids
• other agents such as growth hormone secretagogues
• Bisphosphonates (bisphosphonic acids) are known to inhibit bone resorption and are useful for the treatment of bone lithiasis as disclosed in U.S. Patent 4,621,077 to Rosini, et al.
• the literature discloses a variety of bisphosphonic acids which are useful in the treatment and prevention of diseases involving bone resorption. Representative examples may be found in the following: U.S. Patent No. 3,251,907; U.S. Patent No. 3,422,137; U.S. Patent No. 3,584,125; U.S. Patent No. 3,940,436; U.S. Patent No. 3,944,599; U.S. Patent No. 3,962,432; U.S. Patent No. 4,054,598; U.S. Patent No. 4,267,108; U.S. Patent No. 4,327,039; U.S. Patent No. 4,407,761; U.S. Patent No. 4,578,376; U.S. Patent No. 4,621,077; U.S. Patent No. 4,624,947; U.S. Patent No. 4,746,654; U.S. Patent No. 4,761,406; U.S. Patent No.
• bisphosphonic acids and halo- bisphosphonic acids are well known in the art. Representative examples may be found in the above mentioned references which disclose the compounds as being useful for the treatment of disturbances of calcium or phosphate metabolism, in particular, as inhibitors of bone resorption.
• Preferred bisphosphonates are selected from the group of the following compounds: alendronic acid, etidrononic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, 6-amino-l-hydroxy-hexylidene-bisphosphonic acid, and 1-hydroxy- 3(methylpentylamino)-propylidene-bisphosphonic acid; or any pharmaceutically acceptable salt thereof.
• a particularly preferred bisphosphonate is alendronic acid (alendronate), or a pharmaceutically acceptable salt thereof.
• An especially preferred bisphosphonate is alendronate sodium, including alendronate sodium trihydrate. Alendronate sodium has received regulatory approval for marketing in the United States under the trademark FOSAMAX®.
• a compound of the present invention may be co-administered with a 5 ⁇ -reductase 2 inhibitor, such as finasteride or epristeride; a 5 -reductase 1 inhibitor such as 4,7 ⁇ -dimethyl-4-aza-5 ⁇ - cholestan-3-one, 3-oxo-4-aza-4,7 ⁇ -dimethyl-16 ⁇ -(4-chlorophenoxy)-5 ⁇ - androstane, and 3-oxo-4-aza-4,7 ⁇ -dimethyl-16 ⁇ -(phenoxy)-5 ⁇ -androstane as disclosed in WO 93/23420 and WO 95/11254; dual inhibitors of 5 ⁇ - reductase 1 and 5 ⁇ -reductase 2 such as 3-oxo-4-aza-17 ⁇ -(2,5- trifluoromethylphenyl-carbamoyl)-5 ⁇ -androstane as disclosed in WO 95/07927; antiandrogens such as flutamide, casodex and c
• a compound of the present invention may be used in combination with growth hormone, growth hormone releasing hormone or growth hormone secretagogues, to delay puberty in growth hormone deficient children, which will allow them to continue to gain
• a compound of the present invention may be used in combination or co-administered with a compound having luteinizing hormone releasing activity such as a peptide or natural hormone or analog thereof.
• a compound having luteinizing hormone releasing activity such as a peptide or natural hormone or analog thereof.
• peptide compounds include leuprorelin, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterlin and recirelin.
• the active agents may be administered separately or in conjunction.
• the administration of one element may be prior to, concurrent to, or subsequent to the administration of the other agent.
• the pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
• compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
• Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
• excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
• the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
• a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be
• Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
• an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
• water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
• Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
• excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl- cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan
• the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
• preservatives for example ethyl, or n-propyl, p-hydroxybenzoate
• coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
• coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
• flavoring agents such as sucrose, saccharin or aspartame.
• sweetening agents such as sucrose, saccharin or aspartame.
• Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
• the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
• Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
• a dispersing or wetting agent e.g., sodium EDTA
• suspending agent e.g., sodium EDTA
• preservatives e.g., sodium EDTA, sodium bicarbonate, sodium bicarbonate
• the pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions.
• the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
• Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy beans, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
• the emulsions may also contain sweetening and flavouring agents.
• Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
• sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
• Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
• the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
• This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
• the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
• the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
• sterile, fixed oils are conventionally employed as a solvent or suspending medium.
• any bland fixed oil may be employed including synthetic mono- or diglycerides.
• fatty acids such as oleic acid find use in the preparation of injectables.
• Compounds of Formula I may also be administered in the form of a suppositories for rectal administration of the drug.
• These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
• a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
• Such materials are cocoa butter and polyethylene glycols.
• creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
• the compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art.
• the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
• Compounds of the present invention may also be delivered as a suppository employing bases such as cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
• the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed.
• a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter, arrest or reverse the progress of the condition.
• Optimal precision in achieving concentration of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the
• doses of the compound of structural formula I useful in the method of the present invention range from 0.01 to 1000 mg per adult human per day. Most preferably, dosages range from 0.1 to 500 mg/day.
• the compositions are preferably provided in the form of tablets containing 0.01 to 1000 milligrams of the active ingredient, particularly 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
• An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0002 mg/kg to about 50 mg/kg of body weight per day. The range is more particularly from about 0.001 mg/kg to 1 mg/kg of body weight per day.
• the active agent of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in dividend doses of two, three or four times daily.
• the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration .
• Step 1A Methyl (S)-2-[3-(2-benzyloxy-l-methylethyl)-2-triethylsilyl- lH-pyrrolo[2.3-b]pyridin-5-yn-2-methylpropanoate
• Step IB Methyl GS)-2-[3-(2-benzyloxy-l-methylethyl)-2-iodo-lH- pyrrolof2.3-61pyridin-5-yl1-2-methylpropanoate
• Step 1C Methyl (S -2-[3-(2-benzyloxy-l-methylethyl)-2-(3,5-dimethyl- phenyl)-lH-pyrrolor2.3-b1pyridin-5-yl1-2-methylpropanoate
• methyl (S)-2-[3-(2- benzyloxy-l-methylethyl)-2-iodo-lH-pyrrolo[2,3-b]pyridin-5-yl]-2- methylpropanoate (4.00 g, 8.12 mmol), 2,5-dimethylphenylboronic acid (1.83 g, 12.2 mmol) and Pd(dppf)Cl 2 «CH 2 Cl 2 (0.33 g, 0.406 mmol) in toluene/MeOH (5:2; 140 mL) was degassed via three vacuum/nitrogen ingress cycles and the resulting mixture was heated to approximately 80°C.
• Step IE (S)-l-(N,/V-Diisobutylamino)-2-[3-(2-benzyloxy-l- methylethyl)-2-(3,5-dimethylphenyl)-lH-pyrrolo[2,3-6]- pyridin-5-yll -2-methylpropan- 1-one
• Step 1G (S)-l-CN,N-Diisobutylamino)-2-[3-(2-hydroxy-l-methyl- ethyl)-2-(3,5-dimethylphenyl)-lH-l-(fer£-butoxycarbonyl)- pyrrolo[2.3-6]pyridin-5-yl1-2-methylpropan-l-one
• Step lH (S)-l-(N r N-Diisobutylamino)-2-[3-(2-azido-l-methylethyl)-2- (3,5-dimethylphenyl)-lH-l-(fer£-butoxycarbonyl)pyrrolo- [2.3-61pyridin-5-yl1-2-methylpropan-l-one
• DEAD is added dropwise via syringe to a stirred solution of (S)-l-(iV r /V-diisobutylamino)-2-[3-(2-hydroxy-l-methylethyl)-2-(3,5- dimethylphenyl)-lH-l-( ⁇ ert-butoxycarbonyl)pyrrolo[2,3-6]pyridin-5-yl]- 2-methylpropan-l-one, ZnN 6 «2py, PPh 3 and imidazole in C ⁇ 2 C1 2 at approximately 0°C.
• the reaction mixture is allowed to warm to room temperature overnight, then filtered through celite ® washing copiously with CH 2 C1 2 .
• the filtrate is poured into water and extracted with CH 2 C1 2 , and the combined organic extract is washed with brine, dried (MgSO 4 ) and concentrated in vacuo.
• the residue is purified by flash chromatography on silica gel (gradient elution; 25-40% ethyl acetate/hexanes as eluent) to give the title compound.
• Step II (S)-l-(N,/V-Diisobutylamino)-2-[3-(2-amino-l-methyl- ethyl)-2-(3,5-dimethylphenyl)-lH-l-(_er£-butoxycarbonyl)- pyrrolo [2.3-61 pyridin-5-yll -2-methylpropan- 1-one
• Step 1 J (S)-l-(N N-Diisobutylamino)-2- [3-(2-(2,4-dinitrobenzene- sulfonylamino)-l-methylethyl)-2-(3,5-dimethylphenyl)-lH-l- ( er£-butoxycarbonyl)pyrrolo [2,3-6] pyridin-5-yl] -2-methyl- propan-1-one
• 2,4-Dinitrobenzenesulfonyl chloride is added to a stirred solution of (S)-l-(N ' N-diisobutylamino)-2-[3-(2-amino-l-methylethyl)-2- (3,5-dimethylphenyl)-lH-l-( ⁇ er ⁇ -butoxycarbonyl)pyrrolo[2,3-6]pyridin-5- yl] -2-methylpropan- 1-one and 2,4,6-collidine in CH 2 C1 2 at approximately 0°C. After 5 min, the resulting mixture is warmed to ambient temperature and aged for 2h. The reaction mixture is poured into water and extracted with ethyl acetate.
• Step IK (S)-N- ⁇ 4-(2-[N-(5-[2-( ⁇ ⁇ v r -Diisobutylamino)-l,l-dimethyl-2- oxoethyl]-2-(3,5-dimethylphenyl)-lH-l-(teri£-butoxycarbonyl)- pyrrolo[2,3-6]pyridin-3-yl]propyl)-N-(2,4-dinitrobenzene- sulfonyl)laminoethyl)phenyl)methanesulfonimide
• Step lL (S)-N-[4-(2- ⁇ 2-[5-[2-(iV ⁇ -Diisobutylamino)-l,l-dimethyl-2- oxoethyl] -2-(3 ,5-dimethylphenyl)- 1H- l-(ter -butoxycarbonyl)- pyrrolo[2,3-6]pyridin-3-yl]propylamino ⁇ ethyl)phenyl]- methanesulfonimide rc-Propylamine is added to a stirred solution of (S')-N- ⁇ 4-(2- [AT-(5-[2-(N N-diisobutylamino)-l,l-dimethyl-2-oxoethyl]-2-(3,5-dimethyl- phenyl)-lH-pyrrolo[2,3-6]pyridin-3-yl]propyl)-N-(2,4-dinitrobenzene-
• Step IM (S)-N-[4-(2- ⁇ 2-[5-[2-(iV r ⁇ -Diisobutylamino)-l,l-dimethyl-2- oxoethyl] -2-(3 ,5-dimethylphenyl)- lH-pyrrolo [2,3-6] pyridin- 3-yn-propylamino ⁇ ethyl)pheny ⁇ 1 methanesulfonimide
• the resulting mixture is concentrated in vacuo and the residue partitioned between saturated aqueous NaHCO 3 and CH 2 C1 2 .
• the organic phase is separated and the aqueous phase re-extracted with CH 2 C1 2 .
• the combined organic extract is washed with brine, dried (MgSO 4 ), and concentrated in vacuo.
• the residue containing the title compound is used directly in the next step without further purification.
• Step B Ethyl 2-methyl-2-(pyridin-3-yl)propanoate-iV-oxide eta-chloroperoxybenzoic acid (55%; 21.3 g, 67,9 mmol) was added in one portion to a vigorously stirred emulsion of ethyl 2- methyl-2-(pyridin-3-yl)propanoate and NaHCO 3 (17.5 g, 0.209 mmol) in water/chloroform (1:1; 500 mL) at ambient temperature. After approximately 12 h, the organic phase was separated and the aqueous phase extracted with chloroform (x3). The combined organic extract was washed with brine, dried (MgSO 4 ) and concentrated in vacuo. The residue (10.9 g, 100%) was judged pure by a combination of TLC and H nmr analysis and was used without further purification in the subsequent reaction.
• Step C Ethyl 2-[6-(2,2-dimethyl-4-oxo-4H-l,3-benzoxazin-3-yl)- pyridin-3-yll -2-methylpropanoate
• Step D 2-(6-Aminopyridin-3-yl)-2-methylpropanoic acid hvdrochloride
• Step F Methyl 2-( ⁇ -amino-5-iodopyridin-3-yl)-2-methylpropanoate
• Step AA Methyl CS)-3-benzyloxy-2-methylpropanoate
• Step BB (ff)-3-Benzyloxy-2-methylpropan-l-ol
• reaction was stirred an additional 6 h at room temperature at which point TLC analysis (20% EtOAc-hexane) indicated complete reaction.
• the reaction mixture was then cooled with an external ice-water bath and quenched by serial addition of 11.4 mL water, 11.4 mL of 15% aqueous NaOH, and 34.2 mL water.
• the reaction mixture was then filtered, the solids were washed with EtOAc, the filtrate and washings were combined and evaporated in vacuo. The residue was redissolved in EtOAc, washed with 10% aqueous NaHSO 4 ,
• Step CC (5 f )-3-Benzyloxy-2-methylpropanal
• Step DD (£)-4-Benzyloxy-l.l-dibromo-3-methylbutene
• the stirrer was started and the crude reaction mixture was introduced as a slow stream which resulted in formation of a granular precipitate. After the transfer was complete the reaction mixture was filtered and the solids were carefully washed with hexane. The filtrate was evaporated in vacuo and additional solids were deposited. The residue was resuspended in hexane, filtered and the filtrate reevaporated. The resulting oil was purified by Kugelrohr distillation to afford 46.54 g (81% for two steps) of the title compound as a colorless oil.
• Step EE ( ⁇ S r )-(4-benzyloxy-3-methylbut-l-ynyl)triethylsilane
• An oven dried 100 mL single-necked round bottom flask was equipped with a magnetic stir bar and a septum then charged with 5.171 g (15.5 mmol) of (S)-4-benzyloxy-l,l-dibromo-3-methylbutene and 20 mL of anhydrous THF.
• the reaction mixture was stirred at -78°C under an N 2 atmosphere and 12.4 mL of a 2.5 M solution of n-butyllithium (31.0 mmol) was added dropwise via syringe over 15 min.
• Step AAA 4- [2-(£ ⁇ r£-Butyldimethylsilyloxy)ethy 11 aniline
• Step BBB N- [4-(2-(fe ⁇ Butyldimethylsilyloxy)ethyl)phenyl] - methanesulfonimide
• Step CCC N- [4-(2-Hvdroxyethyl)phenyl1 methanesulfonimide Trifluoroacetic acid (5 mL) was added to a stirred solution of crude N- [4-(2-(fer ⁇ butyldimethylsilyloxy)ethyl)phenyl] methanesulfonimide (3.98 mmol) in CH 2 C1 2 (20 mL) at room temperature.

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Endocrinology (AREA)
• Immunology (AREA)
• Diabetes (AREA)
• Anesthesiology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Reproductive Health (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=26314548

Family Applications (1)

Country Status (5)

Families Citing this family (20)

• 1999
  • 1999-03-29 EP EP99915075A patent/EP1070064A1/de not_active Withdrawn
  • 1999-03-29 CA CA002326140A patent/CA2326140A1/en not_active Abandoned
  • 1999-03-29 WO PCT/US1999/006766 patent/WO1999051596A1/en not_active Application Discontinuation
  • 1999-03-29 AU AU33679/99A patent/AU3367999A/en not_active Abandoned
  • 1999-03-29 JP JP2000542317A patent/JP2002510685A/ja not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events